Buried Science

Remedies › Berberine › Body weight · All remedies for body weight

Berberine and body weight: what the evidence says

Small or mixed human studies suggest berberine may trim body weight by about a kilogram, but results disagree and the largest recent trial found no loss of belly fat.

3/5 Limited

Some human evidence: small trials, trials on a related outcome, or population studies that disagree. How we score

Social media calls berberine 'nature's Ozempic'. The trials do not support that comparison: no trial has compared it with semaglutide or any other weight-loss drug, and the one registered human study of its effect on the GLP-1 hormone was never published.

Pooled results are small and inconsistent. A 2026 analysis of 23 trials found 0.88 kg more weight loss than control; a 2020 analysis found 2.07 kg; two other 2020 analyses found no significant change in body weight at all.

The best-run recent trial gave 337 people with obesity and fatty liver 1 g a day or placebo for six months and found no difference in belly fat or liver fat.

The clearest positive result is narrow: in 113 people with schizophrenia who had gained weight on antipsychotic drugs, berberine reduced weight by about 1.1 kg more than placebo over 12 weeks.

Most weight trials were small and short, and the newest review asks future trials to fix missing blinding and randomization and to report what the capsules actually contained.

We screened all 84 human-study records and read 30 abstracts in full: 15 of the 23 systematic reviews (the rest covered animal studies, PCOS, liver disease or cancer) and 15 of the 39 trials.

The evidence ladder higher rungs count for more
  1. Meta-analyses of trialspooled randomized trials7
  2. Human studiestrials and population studies8
  3. Case reportssingle people0
  4. Animal studiesmostly rodents356
  5. Lab studiescells, test tubes127

The studies in people, read one by one

ResultTypeWhat they didWhat they found
PositiveSystematic review / meta-analysis, 2026Meta-analysis of 23 randomized trials (risk of bias assessed with RoB 2)
Measured: Body weight, BMI, waist		Body weight -0.88 kg (95% CI -1.36 to -0.39), BMI -0.48; authors flag lack of blinding and randomization. PubMed 41310257
PositiveSystematic review / meta-analysis, 2020Meta-analysis of 12 randomized trials
Measured: Body weight, BMI, waist		Body weight -2.07 kg (95% CI -3.09 to -1.05), BMI -0.47, waist -1.08 cm. PubMed 32690176
MixedSystematic review / meta-analysis, 2020Dose-response meta-analysis of 10 trials
Measured: Body weight, BMI, waist		BMI -0.29 and waist -2.75 cm, but no significant change in body weight (-0.11 kg, P = 0.79). PubMed 32379652
No effectSystematic review / meta-analysis, 2020
849 people		Meta-analysis of 12 randomized trials of berberine and barberry
Measured: BMI, body weight, waist		No significant change in BMI or body weight; only waist-to-hip ratio fell slightly. PubMed 32147051
PositiveSystematic review / meta-analysis, 2022Dose-response meta-analysis of randomized trials on heart risk factors
Measured: Body weight		Body weight -0.84 kg (95% CI -1.34 to -0.34); BMI -0.25. PubMed 36313096
PositiveSystematic review / meta-analysis, 2025Meta-analysis of placebo-controlled randomized trials in metabolic syndrome
Measured: Waist, BMI		Waist -3.27 cm (95% CI -4.82 to -1.72); BMI -0.435 (P = 0.043). PubMed 40740996
PositiveSystematic review / meta-analysis, 2026
233 people		Meta-analysis of 3 randomized trials, berberine added to treatment in schizophrenia with metabolic syndrome
Measured: Body weight		Body weight, BMI and waist lower than control (weight SMD -0.56, P = 0.0003). PubMed 42433212
No effectRandomized trial, 2026
337 people		Randomized, double-blind, placebo-controlled, 11 hospitals in China, obesity with fatty liver, 1 g a day for 6 months
Measured: Belly (visceral) fat, liver fat		No difference in visceral fat area (1.4%, 97.5% CI -2.4% to 5.2%) or liver fat; LDL fell slightly. PubMed 41543854
PositiveRandomized trial, 2022
113 people		Randomized, placebo-controlled, schizophrenia with antipsychotic weight gain, 600 mg a day for 12 weeks (Hong Kong)
Measured: Weight gain		Weight -1.08 kg vs placebo (95% CI -1.76 to -0.40); BMI -0.41. PubMed 34931749
No effectRandomized trial, 2021
84 people		Randomized, double-blind, placebo-controlled, Chinese men with high cholesterol, 12 weeks
Measured: BMI, waist-to-hip ratio		No difference from placebo in BMI or waist-to-hip ratio. PubMed 34444711
PositiveRandomized trial, 2015
184 people		Randomized, open-label, fatty liver: lifestyle alone, plus pioglitazone, or plus berberine 0.5 g three times daily, 16 weeks
Measured: Liver fat, body weight		Berberine plus lifestyle reduced liver fat more (52.7% vs 36.4%) and improved body weight more than lifestyle alone (P < 0.05); not blinded. PubMed 26252777
PositiveRandomized trial, 2023
49 people		Randomized, double-blind, placebo-controlled, overweight adults, berberine phytosome for 2 months
Measured: Fat mass, visceral fat		Visceral fat and fat mass fell more than with placebo (P < 0.0001 and P = 0.004). PubMed 37522683
PositiveRandomized trial, 2026
93 people		Randomized, double-blind, placebo-controlled, obesity, berberine 1 g with white mulberry leaf and chromium, 12 weeks (Greece)
Measured: BMI, fat mass		BMI -1.24 vs placebo; no berberine-only arm, so berberine's own share is unknown. PubMed 42738972
PositiveClinical trial, 2012Uncontrolled pilot study, obese white adults, 500 mg three times daily for 12 weeks (USA)
Measured: Body weight		Mild weight loss of about 5 lb per person on average; no comparison group. PubMed 22739410
PositiveRandomized trial, 2021
100 people		Phase 2, randomized, placebo-controlled, HTD1801 (berberine ursodeoxycholate, a drug form), fatty liver and type 2 diabetes, 18 weeks
Measured: Liver fat, weight		Liver fat -4.8% vs -2.0% on placebo (P = 0.011) at 1,000 mg twice daily, with significant weight loss; diarrhoea most common side effect. PubMed 34535644

Where the sources agree, and where they don’t

1 of 5 kinds of source point toward a benefit, 1 toward no effect or harm, 2 are mixed, and 1 has no data yet. Agreement between independent kinds of evidence matters more than the number of papers in any one of them.

Kind of sourcePoints toDetail
Meta-analyses of trialsMixed0 to 2 kg; two found no change
Best recent trial (2026)No effectno change in belly or liver fat
Antipsychotic weight gain trialsPositiveabout 1 kg less gain
GLP-1 ('Ozempic') human testNo datacompleted 2023, never published
Public reportsMixed3 helped, 1 no effect, 4 too early

Beyond Google: 12 findings about Berberine from trial registries, FDA reports and patent offices that a normal search rarely shows. See them

What people report

We read public first-person posts and counted every outcome, good or bad. 8 reports about this condition, read on 2026-10-28; 6 mention side effects.

  • 3Helped
  • 1No effect
  • 0Got worse
  • 0Mixed
  • 4Too early

Why these counts prove nothing on their own: people who post are not a random sample, most take other treatments at the same time, and nobody checks the diagnosis. We show them because they tell researchers what to test next.

Read all 8 reports
  • No effect Lost 4 lb in week one, then nothing; about eighteen months later said it had not worked much and she gave up. Side effects: hunger and rumbling stomach in first days. Mumsnet, 2025-01-18 (Early loss may be normal fluctuation, as she noted.)
  • Helped Taking 500 mg a day and lost 16 lb over about two months. Mumsnet, 2023-06-08 (Poster stresses a strict low-carb diet as well.)
  • Too early About two weeks in, losing weight on a health drive and feels berberine is curbing appetite. Side effects: mild constipation (poster blames diet). Mumsnet, 2023-06-22 (No amounts; had read it can take three months.)
  • Too early Ten days in, lost 4 lb and found appetite lower, while also fasting and eating fewer carbs. Side effects: more frequent bowel movements. Mumsnet, 2023-06-23 (Poster says diet may explain the appetite change.)
  • Helped Took it with myo-inositol for over a year with diet and exercise; lost a stone and a half with no side effects. Mumsnet, 2023-06-22 (Several changes together; poster credits the combination.)
  • Helped Lost 7.6 lb in three weeks and felt appetite suppressed, while also taking a fibre supplement and fasting 18 hours a day. Side effects: gas and bloating in week 3. Mumsnet, 2024-04-20 (Only three weeks; two other weight-loss measures at once.)
  • Too early Took it for one day, was very gassy, and did not take it again. Side effects: gas. Mumsnet, 2022-10-25 (One day only.)
  • Too early Nearly a month in with no ill effects once taken with food; had not weighed yet. Side effects: gas when taken before meals. Mumsnet, 2022-10-30 (No outcome measured.)

Every other paper we found

PubMed returned 672 papers for this search on 2026-10-28. We read the human studies above ourselves. The rest are sorted by type automatically from PubMed's labels, which are sometimes wrong. We removed 9 papers that only share a word with this search.

Animal studies 356
  1. Multi-omics-driven network pharmacology and experimental validation elucidate the therapeutic mechanism Bupi Yichang Pill in ulcerative colitis via the PI3K/Akt/IKK/NF-κB signalingpathway. J Ethnopharmacol, 2027
  2. Interventional Effects and Neurometabolic Regulation of a Panax quinquefolius-Containing Herbal Extract (JYF) in Diazepam Withdrawal Syndrome in Mice. Pharmaceuticals (Basel), 2026
  3. The preventive effects of tetrahydroberberine on male obese mice and its uptake by adipocytes are associated with the D2R-PI3K axis and OCT2. Eur J Pharmacol, 2026
  4. Synergistic Antitumor Effects and Reduced Systemic Toxicity of Berberine Chloride Combined With Cisplatin in a Female BALB/c Mouse Xenograft Model. Cell Biol Int, 2026
  5. Zhuche Pill alleviates DSS-induced colonic epithelial injury in mice: involvement of IL-17/NF-κB and Wnt/β-catenin signaling pathways. J Ethnopharmacol, 2026
  6. Berberine protects against behavioral deficits, memory dysfunction, and callosal demyelination in cuprizone-intoxicated C57BL/6 mice. Iran J Basic Med Sci, 2026
  7. Berberine's Role in Modulating Gut Microbiota and Endocannabinoid System in Colitis-Associated Colorectal Cancer. Mol Nutr Food Res, 2026
  8. [Berberine attenuates necrotizing enterocolitis-associated brain injury via the TLR4/MyD88/NF-κB/NLRP3 pathway]. Zhongguo Dang Dai Er Ke Za Zhi, 2026
  9. Berberine Alleviates Citrobacter rodentium-Induced Colitis with Reduced Epithelial Gasdermin E-Mediated Pyroptosis. Int J Mol Sci, 2026
  10. The Role and Mechanism of Berberine as a Candidate Drug for the Treatment of Radiation-Induced Intestinal Injury. J Cell Mol Med, 2026
  11. Berberine Attenuates Cadmium-Induced Nephrotoxicity by Suppressing LDHA-Mediated Glycolytic Reprogramming and Restoring Mitochondrial TCA Cycle Metabolism. Biomolecules, 2026
  12. Berberine Stabilizes the Arrhythmogenic Substrate in Obese Rats by Klotho-Mediated Attenuation of Oxidative Stress and Inflammation. Int J Mol Sci, 2026
  13. A novel berberine derivative B12 exhibits superior anti-obesity effects via targeting brown and white adipocyte dynamics. Int J Obes (Lond), 2026
  14. Anti-adipogenic cyathane diterpenoids from Onychium japonicum. Org Biomol Chem, 2026
  15. Huanglian wendan decoction attenuates hepatic inflammation and lipogenesis via inhibition of the NF-κB/HDAC1/SREBP-1c axis. J Ethnopharmacol, 2026
  16. Ameliorative effect of Nano berberine in bleomycin- induced lung fibrosis in male rats. Naunyn Schmiedebergs Arch Pharmacol, 2026
  17. Protective effects of Fraxinus xanthoxyloides bark in alloxan-induced diabetic rats: A phytochemical and pharmacological approach. PLoS One, 2026
  18. Comparative pharmacodynamic material basis of oral and colonic administration of Baitouweng decoction in experimental ulcerative colitis. J Ethnopharmacol, 2026
  19. Epi-Berberine Alleviates Ulcerative Colitis, Protects the Intestinal Mucosal Barrier, and Inhibits Colonic Inflammation via Glutaminyl-Peptide Cyclotransferase in a Mouse Model of DSS-Induced Colitis. Phytother Res, 2026
  20. Berberine improves colon damage of ulcerative colitis colonic epithelium by activating TAS2R38 signaling pathway. J Mol Histol, 2026
  21. Berberine reverses impaired adipose angiogenesis to promote beige adipogenesis by HIF-1α/PRDM16 signaling. Phytomedicine, 2026
  22. Jiangtang Tiaozhi formula improves obesity and insulin resistance by inhibiting skeletal muscle inflammation and pyroptosis in diet-induced obese mice. Phytomedicine, 2026
  23. Effects of berberine-Lactobacillus casei complex as antibiotics substitutes on growth performance, health-related parameters, liver and intestinal morphology, and gene expression of broilers. Poult Sci, 2026
  24. Evaluation of the obesogenic role of betel nut extract in mice and its remediation by berberine and orlistat. Toxicon, 2026
  25. Berberine combined with stachyose protects against obesity by modulating gut microbiota and increasing leptin sensitivity. Sci China Life Sci, 2026
  26. Berberine-taxifolin co-administration attenuates inflammatory response and intestinal barrier injury via nf-κB/NLRP3 suppression in colitis. Front Immunol, 2025
  27. Protective effects of berberine-loaded chitosan/solid lipid nanoparticles in streptozotocin-induced gestational diabetes mellitus rats. Exp Biol Med (Maywood), 2025
  28. Modified Guilu Erxian Glue regulates Treg immune function to suppress bone marrow failure in aplastic anemia mice. Chin Med, 2025
  29. Nano-Encapsulated Berberine Is a Potential Therapeutic Agent for Adipose Tissue Browning in C57BL/6J Mice. Medicina (Kaunas), 2025
  30. Coptisine alleviates intestinal barrier dysfunction and inflammation in TNBS-induced colitis rats and LPS-stimulated human intestinal Caco-2 cells. Int Immunopharmacol, 2025
  31. Histological, Immunohistochemical, and Biochemical Evaluation of the Effect of Berberine on Ovarian Hyperstimulation Syndrome in Rats. J Obstet Gynaecol Res, 2025
  32. Berberine contributes to protecting against the cadmium-induced pancreatic damage: role of intestinal microbiome modulation and barrier function. J Mol Histol, 2025
  33. Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway. PLoS One, 2025
  34. Effect of berberine on LPS-induced intestinal epithelial injury and m6A methylation in broilers. Poult Sci, 2025
  35. Oxyberberine alleviates fructose-induced hyperuricemia by modulating purine metabolism and gut microbiota. Eur J Pharmacol, 2025
  36. Berberine Reveals Anticoccidial Activity by Influencing Immune Responses in Eimeria acervulina-Infected Chickens. Biomolecules, 2025
  37. Jatrorrhizine attenuates inflammatory response in Helicobacter pylori-induced gastritis by suppressing NLRP3 inflammasomes and NF-κB signaling pathway. Arch Microbiol, 2025
  38. Fufang zhenzhu tiaozhi capsule alleviates hypothalamic endoplasmic reticulum stress and leptin resistance through autophagy modulation in DIO rats. J Ethnopharmacol, 2025
  39. Combination of Berberine and Evodiamine Alleviates Obesity by Promoting Browning in 3T3-L1 Cells and High-Fat Diet-Induced Mice. Int J Mol Sci, 2025
  40. Berberine Alleviates 1-Methyl-3-Nitro-1-Nitrosoguanidine- Induced Chronic Atrophic Gastritis in Rats. Turk J Gastroenterol, 2025
  41. Nutraceutical supplement slim reshaped colon histomorphology and reduces Mucispirillum schaedleri in obese mice. Front Microbiol, 2025
  42. Study on the mechanism of action of berberine combined with Jianpi Yishen Huazhuo formulation in treating obese polycystic ovary syndrome by activating PI3K/AKT signaling pathway. Gynecol Endocrinol, 2025
  43. Berberine attenuates obesity-induced skeletal muscle atrophy via regulation of FUNDC1 in skeletal muscle of mice. Sci Rep, 2025
  44. Residual and pharmacokinetic behavior of berberine in Carassius auratus under intraperitoneal injection conditions by HPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci, 2025
  45. Epiberberine Improves Hyperglycemia and Ameliorates Insulin Sensitivity in Type 2 Diabetic Mice. Nephrology (Carlton), 2025
  46. Berberine Improves Glucose and Lipid Metabolism in Obese Mice Through the Reduction of IRE1/GSK-3β Axis-Mediated Inflammation. Endocr Metab Immune Disord Drug Targets, 2025
  47. Potentiation and in vivo evaluation of anti-obesity activity of berberine through encapsulation in guar-acacia gum nanocomplexes. Naunyn Schmiedebergs Arch Pharmacol, 2025
  48. Exploring the relaxation effects of Coptis chinensis and berberine on the lower esophageal sphincter: potential strategies for LES motility disorders. BMC Complement Med Ther, 2024
  49. Berberine alleviates ETEC-induced intestinal inflammation and oxidative stress damage by optimizing intestinal microbial composition in a weaned piglet model. Front Immunol, 2024
  50. Intestinal and hepatic benefits of BBR-EVO on DSS-induced experimental colitis in mice. Front Microbiol, 2024
  51. Berberine Inhibits Ferroptosis and Stabilizes Atherosclerotic Plaque through NRF2/SLC7A11/GPX4 Pathway. Chin J Integr Med, 2024
  52. Effect of berberine combined with metformin on autophagy in polycystic ovary syndrome by regulating AMPK/AKT/mTOR pathway. Mol Reprod Dev, 2024
  53. Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome. J Ethnopharmacol, 2024
  54. Preventive effects of a nutraceutical mixture of berberine, citrus and apple extracts on metabolic disturbances in Zucker fatty rats. PLoS One, 2024
  55. Anti-Inflammatory Effects of Zinc Oxide and Berberine in Rats with Dextran Sulfate Sodium (DSS)-Induced Colitis. Animals (Basel), 2024
  56. Neuroprotective Potentials of Berberine in Rotenone-Induced Parkinson's Disease-like Motor Symptoms in Rats. Brain Sci, 2024
  57. Tetrahydroberberrubine exhibits preventive effect on obesity by activating PGC1α-mediated thermogenesis in white and brown adipose tissue. Biochem Pharmacol, 2024
  58. Improvement effects of a novel Chinese herbal formula in imiquimod and IL-23-stimulated mouse models of psoriasis. Chin Med, 2024
  59. Berberine alleviates ovarian tissue damage in mice with hepatolenticular degeneration by suppressing ferroptosis and endoplasmic reticulum stress. J Integr Med, 2024
  60. Berberine Improves Cancer-Derived Myocardial Impairment in Experimental Cachexia Models by Targeting High-Mobility Group Box-1. Int J Mol Sci, 2024
  61. The combination of berberine and isoliquiritigenin synergistically improved adipose inflammation and obesity-induced insulin resistance. Phytother Res, 2024
  62. Berberine attenuates obesity-induced insulin resistance by inhibiting miR-27a secretion. Diabet Med, 2024
  63. Mechanism of the components compatibility of Scutellariae Radix and Coptidis Rhizoma on mice with hyperlipidemia by regulating the Cyp4a family. J Ethnopharmacol, 2024
  64. Huanglian-banxia promotes gastric motility of diabetic rats by modulating brain-gut neurotransmitters through MAPK signaling pathway. Neurogastroenterol Motil, 2024
  65. Beneficial Effects of Natural Alkaloids from Berberis glaucocarpa as Antidiabetic Agents: An In Vitro, In Silico, and In Vivo Approach. ACS Omega, 2024
  66. A Dual Therapeutic Approach to Diabetes Mellitus via Bioactive Phytochemicals Found in a Poly Herbal Extract by Restoration of Favorable Gut Flora and Related Short-Chain Fatty Acids. Appl Biochem Biotechnol, 2024
  67. Berberine Metabolites Stimulate GLP-1 Secretion by Alleviating Oxidative Stress and Mitochondrial Dysfunction. Am J Chin Med, 2024
  68. Berberine ameliorates glucocorticoid-induced hyperglycemia: an in vitro and in vivo study. Naunyn Schmiedebergs Arch Pharmacol, 2024
  69. Acute and 90-day toxicological safety assessment of Shang-Ke-Huang-Shui lotion in New Zealand White rabbits. J Ethnopharmacol, 2024
  70. Combination of Coptis chinensis polysaccharides and berberine ameliorates ulcerative colitis by regulating gut microbiota and activating AhR/IL-22 pathway. J Ethnopharmacol, 2024
  71. Antioxidant and antiarthritic potential of berberine: In vitro and in vivo studies. Chin Herb Med, 2023
  72. Berberine protects cyclophosphamide and busulfan-induced premature ovarian insufficiency in mouse model. J Pharmacol Sci, 2023
  73. Ameliorative effects of the Coptis inflorescence extract against lung injury in diabetic mice by regulating AMPK/NEU1 signaling. Phytomedicine, 2023
  74. Berberine Reduces Lipid Accumulation in Obesity via Mediating Transcriptional Function of PPARδ. Int J Mol Sci, 2023
  75. [Equivalence of combined decoction and mixed single decoctions of Gegen Qinlian Decoction in alleviating chemotherapy-associated diarrhea]. Zhongguo Zhong Yao Za Zhi, 2023
  76. Oxyberberine ameliorates TNBS-induced colitis in rats through suppressing inflammation and oxidative stress via Keap1/Nrf2/NF-κB signaling pathways. Phytomedicine, 2023
  77. Oral administration of Huanglian-Houpo herbal nanoemulsion loading multiple phytochemicals for ulcerative colitis therapy in mice. Drug Deliv, 2023
  78. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. Biomed Pharmacother, 2023
  79. High fructose-induced skeletal muscle insulin resistance could be alleviated by berberine via AMPD1 and ADSL. Food Chem Toxicol, 2023
  80. Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents. Molecules, 2023
  81. Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes. Endocrinology, 2023
  82. Gut microbiota-SCFAs-brain axis associated with the antidepressant activity of berberine in CUMS rats. J Affect Disord, 2023
  83. Berberine alleviates intestinal barrier dysfunction in glucolipid metabolism disorder hamsters by modulating gut microbiota and gut-microbiota-related tryptophan metabolites. J Sci Food Agric, 2023
  84. Anti-obesity and Gut Microbiota Modulation Effect of Astragalus Polysaccharides Combined with Berberine on High-Fat Diet-Fed Obese Mice. Chin J Integr Med, 2023
  85. Study of Hypoglycemic Activity of Novel 9-N-alkyltetrahydroberberine Derivatives. Int J Mol Sci, 2022
  86. Oral berberine ameliorates high-fat diet-induced obesity by activating TAS2Rs in tuft and endocrine cells in the gut. Life Sci, 2022
  87. Berberine Depresses Inflammation and Adjusts Smooth Muscle to Ameliorate Ulcerative Colitis of Cats by Regulating Gut Microbiota. Microbiol Spectr, 2022
  88. The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression. Biomed Pharmacother, 2022
  89. Berberine ameliorates pulmonary inflammation in mice with influenza viral pneumonia by inhibiting NLRP3 inflammasome activation and gasdermin D-mediated pyroptosis. Drug Dev Res, 2022
  90. Qingchang Wenzhong Decoction Alleviates DSS-Induced Inflammatory Bowel Disease by Inhibiting M1 Macrophage Polarization In Vitro and In Vivo. Biomed Res Int, 2022
  91. [Effects of berberine on LPS /NF-κB and MAPK signaling pathways in PCOS model rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2022
  92. Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats. Drug Deliv, 2022
  93. Toxicity and toxicokinetics of the ethanol extract of Zuojin formula. BMC Complement Med Ther, 2022
  94. Berberine ameliorates mesenteric vascular dysfunction by modulating perivascular adipose tissue in diet-induced obese in rats. BMC Complement Med Ther, 2022
  95. Berberine Ameliorates Insulin Resistance by Inhibiting IKK/NF-κB, JNK, and IRS-1/AKT Signaling Pathway in Liver of Gestational Diabetes Mellitus Rats. Metab Syndr Relat Disord, 2022
  96. Jatrorrhizine from Rhizoma Coptidis exerts an anti-obesity effect in db/db mice. J Ethnopharmacol, 2022
  97. Berberine-mediated REDD1 down-regulation ameliorates senescence of retinal pigment epithelium by interrupting the ROS-DDR positive feedback loop. Phytomedicine, 2022
  98. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. Food Funct, 2022
  99. Modulation of Gut Microbiota and Metabolites by Berberine in Treating Mice With Disturbances in Glucose and Lipid Metabolism. Front Pharmacol, 2022
  100. [Mechanism of Huanglian Houpo Decoction in treatment of ulcerative colitis in mice based on brain-gut axis]. Zhongguo Zhong Yao Za Zhi, 2022
  101. Berberis dictyophylla F. inhibits angiogenesis and apoptosis of diabetic retinopathy via suppressing HIF-1α/VEGF/DLL-4/Notch-1 pathway. J Ethnopharmacol, 2022
  102. Protective Effects of Oxyberberine in 5-Fluorouracil-Induced Intestinal Mucositis in the Mice Model. Evid Based Complement Alternat Med, 2022
  103. Berberine retarded the growth of gastric cancer xenograft tumors by targeting hepatocyte nuclear factor 4α. World J Gastrointest Oncol, 2022
  104. Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway In Vivo and In Vitro. Front Pharmacol, 2022
  105. Effect of berberine on copper and zinc levels in chickens infected with Eimeria tenella. Mol Biochem Parasitol, 2022
  106. [Experimental study on the regulation of subchondral bone plate osteoprotegerin/receptor activator of nuclear factor kappa-B ligand system by berberine to retard the development of osteoarthritis in rabbits]. Zhongguo Gu Shang, 2022
  107. Berberine attenuates sepsis-induced cardiac dysfunction by upregulating the Akt/eNOS pathway in mice. Exp Ther Med, 2022
  108. Concerted action of berberine in the porcine intestinal epithelial model IPEC-J2: Effects on tight junctions and apoptosis. Physiol Rep, 2022
  109. Berberine attenuates hyperalgesia in mice with adenomyosis. Arch Gynecol Obstet, 2022
  110. Pre-Administration of Berberine Exerts Chemopreventive Effects in AOM/DSS-Induced Colitis-Associated Carcinogenesis Mice via Modulating Inflammation and Intestinal Microbiota. Nutrients, 2022
  111. Shenlian (SL) Decoction, a Traditional Chinese Medicine Compound, May Ameliorate Blood Glucose via Mediating the Gut Microbiota in db/db Mice. J Diabetes Res, 2022
  112. Regulation of the kynurenine/serotonin pathway by berberine and the underlying effect in the hippocampus of the chronic unpredictable mild stress mice. Behav Brain Res, 2022
  113. Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition. J Cell Mol Med, 2022
  114. Green-synthetized selenium nanoparticles using berberine as a promising anticancer agent. J Integr Med, 2022
  115. Effects of berberine on the pharmacokinetics of florfenicol and levels of cytochrome P450 3A37, multidrug resistance 1, and chicken xenobiotic-sensing orphan nuclear receptor mRNA expression in broilers. Vet Med Sci, 2022
  116. Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3. Acta Pharmacol Sin, 2022
  117. Berberine alleviates monosodium glutamate induced postnatal metabolic disorders associated vascular endothelial dysfunction in newborn rats: possible role of matrix metalloproteinase-1. Arch Physiol Biochem, 2022
  118. Berberine Relieves Metabolic Syndrome in Mice by Inhibiting Liver Inflammation Caused by a High-Fat Diet and Potential Association With Gut Microbiota. Front Microbiol, 2021
  119. Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice. Int J Mol Sci, 2021
  120. Synergetic protective effect of berberine and ginsenoside Rb1 against tumor necrosis factor alpha-induced inflammation in adipocytes. Bioengineered, 2021
  121. Anticoccidial Activity of Berberine against Eimeria-Infected Chickens. Korean J Parasitol, 2021
  122. Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway. Int J Biol Sci, 2021
  123. The protective impact of berberine against doxorubicin-induced nephrotoxicity in rats. Tissue Cell, 2021
  124. Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice. Life Sci, 2021
  125. Lagerstroemia speciosa (L.) Pers., ethanolic extract attenuates simultaneously administered isoniazid- and dapsone-induced hepatotoxicity in rats. J Food Biochem, 2021
  126. Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent manner. Pharmacol Res, 2021
  127. Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. Front Endocrinol (Lausanne), 2021
  128. Activity of Compound Agrimony Enteritis Capsules against invasive candidiasis: Exploring the differences between traditional Chinese medicine prescriptions and its main components in the treatment of diseases. J Ethnopharmacol, 2021
  129. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. Int J Biol Sci, 2021
  130. Amelioration of diabetic retinopathy in db/db mice by treatment with different proportional three active ingredients from Tibetan medicine Berberis dictyophylla F. J Ethnopharmacol, 2021
  131. In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications. J Ethnopharmacol, 2021
  132. The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice. Nutrients, 2021
  133. Prebiotic Effect of Berberine and Curcumin Is Associated with the Improvement of Obesity in Mice. Nutrients, 2021
  134. Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. NPJ Biofilms Microbiomes, 2021
  135. Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. Phytomedicine, 2021
  136. The Effect of Berberine, a Drug From Chinese Folk Medicine, on Serum and Urinary Uric Acid Levels in Rats With Hyperuricemia. Cureus, 2021
  137. Effect of berberine on hyperglycaemia and gut microbiota composition in type 2 diabetic Goto-Kakizaki rats. World J Gastroenterol, 2021
  138. Berberine elevates mitochondrial membrane potential and decreases reactive oxygen species by inhibiting the Rho/ROCK pathway in rats with diabetic encephalopathy. Mol Pain, 2021
  139. Berberine improves dietary-induced cardiac remodeling by upregulating Kruppel-like factor 4-dependent mitochondrial function. Biol Chem, 2021
  140. Dietary supplementation with berberine improves growth performance and modulates the composition and function of cecal microbiota in yellow-feathered broilers. Poult Sci, 2021
  141. Coptisine ameliorates DSS-induced ulcerative colitis via improving intestinal barrier dysfunction and suppressing inflammatory response. Eur J Pharmacol, 2021
  142. Berberine ameliorates ovariectomy-induced anxiety-like behaviors by enrichment in equol generating gut microbiota. Pharmacol Res, 2021
  143. Supplemental Berberine in a High-Fat Diet Reduces Adiposity and Cardiac Dysfunction in Offspring of Mouse Dams with Gestational Diabetes Mellitus. J Nutr, 2021
  144. An integrated network pharmacology and transcriptomic method to explore the mechanism of the total Rhizoma Coptidis alkaloids in improving diabetic nephropathy. J Ethnopharmacol, 2021
  145. Moderate exercise ameliorates osteoarthritis by reducing lipopolysaccharides from gut microbiota in mice. Saudi J Biol Sci, 2021
  146. Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis. Reprod Biol Endocrinol, 2021
  147. The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis. Drug Metab Dispos, 2021
  148. Thalictrum minus L. ameliorates particulate matter-induced acute lung injury in mice. J Ethnopharmacol, 2021
  149. Berberine for Appetite Suppressant and Prevention of Obesity. Biomed Res Int, 2020
  150. Berberine Down-Regulated Myostatin Expression and Facilitated Metabolism via Smad Pathway in Insulin Resistant Mice. Diabetes Metab Syndr Obes, 2020
  151. Berberine Improves Inflammatory Responses of Diabetes Mellitus in Zucker Diabetic Fatty Rats and Insulin-Resistant HepG2 Cells through the PPM1B Pathway. J Immunol Res, 2020
  152. Dose-dependent beneficial and harmful effects of berberine on mouse oocyte maturation and fertilization and fetal development. Toxicol Res (Camb), 2020
  153. Regulation of MFN2 by berberine alleviates obesity exacerbated colitis. Biochem Biophys Res Commun, 2020
  154. Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance via reduction in association of the Glucocorticoid Receptor with phosphatidylinositol-3-kinase. Int J Biol Sci, 2020
  155. Xiaokeyinshui extract combination, a berberine-containing agent, exerts anti-diabetic and renal protective effects on rats in multi-target mechanisms. J Ethnopharmacol, 2020
  156. Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway. Curr Med Sci, 2020
  157. Therapeutic Effect of Berberine on Insomnia Rats by ErbB Signaling Pathway. Med Sci Monit, 2020
  158. Systematic screening and characterization of absorbed constituents and in vivo metabolites in rats after oral administration of Rhizoma coptidis using UPLC-Q-TOF/MS. Biomed Chromatogr, 2020
  159. ATP reduces mitochondrial MECR protein in liver of diet-induced obese mice in mechanism of insulin resistance. Biosci Rep, 2020
  160. Berberine induces lipolysis in porcine adipocytes by activating the AMP‑activated protein kinase pathway. Mol Med Rep, 2020
  161. The Protective Effect of Different Polar Solvent Extracts of Er Miao San on Rats with Adjuvant Arthritis. Evid Based Complement Alternat Med, 2020
  162. Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels. Life Sci, 2020
  163. Berberine combined with cyclosporine A alleviates acute graft-versus-host disease in murine models. Int Immunopharmacol, 2020
  164. Berberine regulates fecal metabolites to ameliorate 5-fluorouracil induced intestinal mucositis through modulating gut microbiota. Biomed Pharmacother, 2020
  165. Development of a Novel Anti-Obesity Compound with Inhibiting Properties on the Lipid Accumulation in 3T3-L1 Adipocytes. Iran Biomed J, 2020
  166. Berberine Inhibits Adipogenesis in Porcine Adipocytes via AMP-Activated Protein Kinase-Dependent and -Independent Mechanisms. Lipids, 2019
  167. Berberine attenuates olanzapine induced-metabolic syndrome. J Pak Med Assoc, 2019
  168. Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice. Biomed Pharmacother, 2019
  169. Berberine inhibits adipocyte differentiation, proliferation and adiposity through down-regulating galectin-3. Sci Rep, 2019
  170. Berberine chloride ameliorated PI3K/Akt-p/SIRT-1/PTEN signaling pathway in insulin resistance syndrome induced in rats. J Food Biochem, 2019
  171. Simultaneous Determination of Seven Active Components in Rat Plasma by UHPLC-MS/MS and Application to a Quantitative Study after Oral Administration of Huang-Lian Jie-Du Decoction in High Fat-Induced Atherosclerosis Rats. Int J Anal Chem, 2019
  172. Glucose consumption assay discovers coptisine with beneficial effect on diabetic mice. Eur J Pharmacol, 2019
  173. Effects of berberine on the growth performance, antioxidative capacity and immune response to lipopolysaccharide challenge in broilers. Anim Sci J, 2019
  174. Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. Cell Death Dis, 2019
  175. Berberine ameliorates diabetic neuropathic pain in a rat model: involvement of oxidative stress, inflammation, and μ-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol, 2019
  176. Berberine hydrochloride protects against cytokine-induced inflammation through multiple pathways in undifferentiated C2C12 myoblast cells. Can J Physiol Pharmacol, 2019
  177. Berberine stimulates fibroblast growth factor 21 by modulating the molecular clock component brain and muscle Arnt-like 1 in brown adipose tissue. Biochem Pharmacol, 2019
  178. A novel berberine-metformin hybrid compound exerts therapeutic effects on obese type 2 diabetic rats. Clin Exp Pharmacol Physiol, 2019
  179. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. Curr Med Sci, 2019
  180. Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway. Exp Ther Med, 2019
  181. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3. FASEB J, 2019
  182. Diversity of the Gut Microbiota in Dihydrotestosterone-Induced PCOS Rats and the Pharmacologic Effects of Diane-35, Probiotics, and Berberine. Front Microbiol, 2019
  183. Protective effects of berberine hydrochloride on DSS-induced ulcerative colitis in rats. Int Immunopharmacol, 2019
  184. Berberine, a Traditional Chinese Medicine, Reduces Inflammation in Adipose Tissue, Polarizes M2 Macrophages, and Increases Energy Expenditure in Mice Fed a High-Fat Diet. Med Sci Monit, 2019
  185. The Role of Berberine in the Prevention of HIF-1α Activation to Alleviate Adipose Tissue Fibrosis in High-Fat-Diet-Induced Obese Mice. Evid Based Complement Alternat Med, 2018
  186. Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. Biomed Pharmacother, 2018
  187. Effects of berberine on tumor growth and intestinal permeability in HCT116 tumor-bearing mice using polyamines as targets. Biomed Pharmacother, 2018
  188. Restoration of GLP-1 secretion by Berberine is associated with protection of colon enterocytes from mitochondrial overheating in diet-induced obese mice. Nutr Diabetes, 2018
  189. Possible therapeutic potential of berberine in the treatment of STZ plus HFD-induced diabetic osteoporosis. Biomed Pharmacother, 2018
  190. The Effects of Berberine on the Gut Microbiota in Apc min/+ Mice Fed with a High Fat Diet. Molecules, 2018
  191. Hepatoprotective effects of berberine on acetaminophen-induced hepatotoxicity in mice. Biomed Pharmacother, 2018
  192. Berberine alleviates adipose tissue fibrosis by inducing AMP-activated kinase signaling in high-fat diet-induced obese mice. Biomed Pharmacother, 2018
  193. Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. Biol Res, 2018
  194. Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. Exp Clin Endocrinol Diabetes, 2018
  195. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. Biomed Pharmacother, 2018
  196. Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe-/- mice. Atherosclerosis, 2018
  197. Berberine impairs embryonic development in vitro and in vivo through oxidative stress-mediated apoptotic processes. Environ Toxicol, 2018
  198. 8-Cetylberberine inhibits growth of lung cancer in vitro and in vivo. Life Sci, 2018
  199. Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21. Br J Pharmacol, 2018
  200. Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats. Lipids Health Dis, 2017
  201. Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats. Pharmacogn Mag, 2017
  202. Berberine ameliorates non-alcoholic steatohepatitis in ApoE-/- mice. Exp Ther Med, 2017
  203. Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway. Bosn J Basic Med Sci, 2017
  204. Berberine chloride ameliorates oxidative stress, inflammation and apoptosis in the pancreas of Streptozotocin induced diabetic rats. Biomed Pharmacother, 2017
  205. The design and synthesis of a novel compound of berberine and baicalein that inhibits the efficacy of lipid accumulation in 3T3-L1 adipocytes. Bioorg Med Chem, 2017
  206. Berberine ameliorates methotrexate-induced liver injury by activating Nrf2/HO-1 pathway and PPARγ, and suppressing oxidative stress and apoptosis in rats. Biomed Pharmacother, 2017
  207. The protective effect of coptisine on experimental atherosclerosis ApoE-/- mice is mediated by MAPK/NF-κB-dependent pathway. Biomed Pharmacother, 2017
  208. Immunoregulatory effects of the traditional Dai prescription Yajieshaba on food allergic mice. Exp Ther Med, 2017
  209. Preventive effect of berberine against DMBA-induced breast cancer in female Sprague Dawley rats. Biomed Pharmacother, 2017
  210. Berberine activates AMPK to suppress proteolytic processing, nuclear translocation and target DNA binding of SREBP-1c in 3T3-L1 adipocytes. Mol Med Rep, 2017
  211. Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels. Mol Med Rep, 2017
  212. Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice. Drug Des Devel Ther, 2017
  213. Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. Mol Med Rep, 2017
  214. Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement. Biomed Pharmacother, 2017
  215. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord, 2017
  216. Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy. Mol Cell Endocrinol, 2017
  217. Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice. Toxicol Appl Pharmacol, 2017
  218. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. Mol Pharmacol, 2017
  219. Demethyleneberberine alleviates inflammatory bowel disease in mice through regulating NF-κB signaling and T-helper cell homeostasis. Inflamm Res, 2017
  220. Nandinine, a Derivative of Berberine, Inhibits Inflammation and Reduces Insulin Resistance in Adipocytes via Regulation of AMP-Kinase Activity. Planta Med, 2017
  221. Effects of isoquinoline alkaloid berberine on lipid peroxidation, antioxidant defense system, and liver damage induced by lead acetate in rats. Redox Rep, 2017
  222. [Effect of protein intervention on amino acid metabolism spectrum of Qi and Yin deficiency type 2 diabetic rats]. Zhongguo Zhong Yao Za Zhi, 2016
  223. Berberine increases adipose triglyceride lipase in 3T3-L1 adipocytes through the AMPK pathway. Lipids Health Dis, 2016
  224. 13-Methylberberine, a berberine analogue with stronger anti-adipogenic effects on mouse 3T3-L1 cells. Sci Rep, 2016
  225. Modulation of Microbiota-Gut-Brain Axis by Berberine Resulting in Improved Metabolic Status in High-Fat Diet-Fed Rats. Obes Facts, 2016
  226. Effect of berberine on the ratio of high-molecular weight adiponectin to total adiponectin and adiponectin receptors expressions in high-fat diet fed rats. Chin J Integr Med, 2016
  227. Berberine Alleviates Olanzapine-Induced Adipogenesis via the AMPKα-SREBP Pathway in 3T3-L1 Cells. Int J Mol Sci, 2016
  228. Berberine protects against memory impairment and anxiogenic-like behavior in rats submitted to sporadic Alzheimer's-like dementia: Involvement of acetylcholinesterase and cell death. Neurotoxicology, 2016
  229. Inhibition of M1 macrophage activation in adipose tissue by berberine improves insulin resistance. Life Sci, 2016
  230. In Vivo Interrelationship between Insulin Resistance and Interferon Gamma Production: Protective and Therapeutic Effect of Berberine. Evid Based Complement Alternat Med, 2016
  231. Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. Mol Med Rep, 2016
  232. Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds. J Transl Med, 2016
  233. Antioxidant and Anti-Inflammatory Effects of Rhei Rhizoma and Coptidis Rhizoma Mixture on Reflux Esophagitis in Rats. Evid Based Complement Alternat Med, 2016
  234. Antihyperglycemia and Antihyperlipidemia Effect of Protoberberine Alkaloids From Rhizoma Coptidis in HepG2 Cell and Diabetic KK-Ay Mice. Drug Dev Res, 2016
  235. Protective mechanisms of berberine against experimental autoimmune myocarditis in a rat model. Biomed Pharmacother, 2016
  236. Protective effect of berberine on doxorubicin‑induced acute hepatorenal toxicity in rats. Mol Med Rep, 2016
  237. Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses. Pharmacol Res, 2016
  238. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity. Sci Rep, 2016
  239. Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. Arch Iran Med, 2016
  240. Inhibitory effects of compounds isolated from the dried branches and leaves of murta (Myrceugenia euosma) on lipid accumulation in 3T3-L1 cells. J Nat Med, 2016
  241. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. Sci Rep, 2016
  242. Neuroprotective effect of berberine is mediated by MAPK signaling pathway in experimental diabetic neuropathy in rats. Eur J Pharmacol, 2016
  243. Hypolipidemic Effects of Alkaloids from Rhizoma Coptidis in Diet-Induced Hyperlipidemic Hamsters. Planta Med, 2016
  244. Synergistic approach for treatment of chicken coccidiosis using berberine--A plant natural product. Microb Pathog, 2016
  245. Epiberberine reduces serum cholesterol in diet-induced dyslipidemia Syrian golden hamsters via network pathways involving cholesterol metabolism. Eur J Pharmacol, 2016
  246. [Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2015
  247. Effects of Berberine on Adipose Tissues and Kidney Function in 3T3-L1 Cells and Spontaneously Hypertensive Rats. Nat Prod Commun, 2015
  248. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep, 2015
  249. Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice. Int J Nanomedicine, 2015
  250. Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds. Lipids Health Dis, 2015
  251. Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats. Eur J Pharmacol, 2015
  252. Anti-adipogenic effect of epiberberine is mediated by regulation of the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways. Arch Pharm Res, 2015
  253. Coptisine attenuates obesity-related inflammation through LPS/TLR-4-mediated signaling pathway in Syrian golden hamsters. Fitoterapia, 2015
  254. Protective effects of berberine against doxorubicin-induced cardiotoxicity in rats by inhibiting metabolism of doxorubicin. Xenobiotica, 2015
  255. Berberine Suppresses Adipocyte Differentiation via Decreasing CREB Transcriptional Activity. PLoS One, 2015
  256. Berberine nanosuspension enhances hypoglycemic efficacy on streptozotocin induced diabetic C57BL/6 mice. Evid Based Complement Alternat Med, 2015
  257. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment. Antimicrob Agents Chemother, 2015
  258. Banxia xiexin decoction protects against dextran sulfate sodium-induced chronic ulcerative colitis in mice. J Ethnopharmacol, 2015
  259. Pharmacokinetic difference of berberine between normal and chronic visceral hypersensitivity irritable bowel syndrome rats and its mechanism. Arch Pharm Res, 2015
  260. Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. Biomed Res Int, 2015
  261. Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. Mol Carcinog, 2015
  262. Pharmacokinetics of two alkaloids after oral administration of rhizoma coptidis extract in normal rats and irritable bowel syndrome rats. Evid Based Complement Alternat Med, 2014
  263. The Rhizome Mixture of Anemarrhena asphodeloides and Coptidis chinensis Ameliorates Acute and Chronic Colitis in Mice by Inhibiting the Binding of Lipopolysaccharide to TLR4 and IRAK1 Phosphorylation. Evid Based Complement Alternat Med, 2014
  264. Shensong Yangxin Capsule prevents diabetic myocardial fibrosis by inhibiting TGF-β1/Smad signaling. J Ethnopharmacol, 2014
  265. Coptidis rhizome and Si Jun Zi Tang can prevent Salmonella enterica serovar Typhimurium infection in mice. PLoS One, 2014
  266. Coptis chinensis alkaloids exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP-α and PPAR-γ. Fitoterapia, 2014
  267. Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine. BMC Complement Altern Med, 2014
  268. The renoprotective effects of berberine via the EP4-Gαs-cAMP signaling pathway in different stages of diabetes in rats. J Recept Signal Transduct Res, 2014
  269. Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages. Int J Mol Med, 2014
  270. Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats. J Transl Med, 2014
  271. Metformin and berberine prevent olanzapine-induced weight gain in rats. PLoS One, 2014
  272. Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. Eur J Pharmacol, 2014
  273. Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase. Life Sci, 2014
  274. In vivo anticoccidial activity of berberine [18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-benzodioxolo(5,6-a) quinolizinium]--an isoquinoline alkaloid present in the root bark of Berberis lycium. Phytomedicine, 2014
  275. Hypolipidemic effect of the Chinese polyherbal Huanglian Jiedu decoction in type 2 diabetic rats and its possible mechanism. Phytomedicine, 2014
  276. Berberine in combination with doxorubicin suppresses growth of murine melanoma B16F10 cells in culture and xenograft. Phytomedicine, 2014
  277. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int J Nanomedicine, 2013
  278. Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation. Mitochondrion, 2013
  279. The effects of Forsythia suspensa extract and berberine on growth performance, immunity, antioxidant activities, and intestinal microbiota in broilers under high stocking density. Poult Sci, 2013
  280. Berberine chloride improved synaptic plasticity in STZ induced diabetic rats. Metab Brain Dis, 2013
  281. Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-κB dependant TGF-β activation: a biphasic experimental study. Toxicol Lett, 2013
  282. Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats. Mol Biol Rep, 2013
  283. Antihyperglycemic effect of the traditional Chinese scutellaria-coptis herb couple and its main components in streptozotocin-induced diabetic rats. J Ethnopharmacol, 2013
  284. A preliminary investigation of the mechanisms underlying the effect of berberine in preventing high-fat diet-induced insulin resistance in rats. J Physiol Pharmacol, 2012
  285. Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking. Phytomedicine, 2012
  286. Anti-hyperglycemic effects and mechanism of traditional Chinese medicine Huanglian Wan in streptozocin-induced diabetic rats. J Ethnopharmacol, 2012
  287. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One, 2012
  288. The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. Lipids Health Dis, 2012
  289. Protective effects of berberine on doxorubicin-induced hepatotoxicity in mice. Biol Pharm Bull, 2012
  290. Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine, 2012
  291. A combination of metabolomics and metallomics studies of urine and serum from hypercholesterolaemic rats after berberine injection. Anal Bioanal Chem, 2012
  292. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes, 2012
  293. Protective effect of berberine on serum glucose levels in non-obese diabetic mice. Int Immunopharmacol, 2012
  294. Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol, 2012
  295. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim Biophys Acta, 2012
  296. Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice. Planta Med, 2012
  297. Berberine prevents 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis: a biochemical approach. Eur J Cancer Prev, 2012
  298. Inhibition of preadipocyte differentiation and lipid accumulation by Orengedokuto treatment of 3T3-L1 cultures. Phytother Res, 2012
  299. [Effect of berberine on expression of transforming growth factor-beta1 and type IV collagen proteins in mesangial cells of diabetic rats with nephropathy]. Zhongguo Zhong Yao Za Zhi, 2011
  300. Berberine attenuates doxorubicin-induced cardiotoxicity in mice. J Int Med Res, 2011
  301. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One, 2011
  302. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol, 2011
  303. [Effects and mechanism of berberine on the hypertensive renal injury rats induced by enriched high fat-salt-fructose diet]. Zhong Yao Cai, 2011
  304. Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. Eur J Pharm Sci, 2011
  305. Berberine, an isoquinoline alkaloid in herbal plants, protects pancreatic islets and serum lipids in nonobese diabetic mice. J Agric Food Chem, 2011
  306. Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver x receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters. Biol Pharm Bull, 2011
  307. [Changes of metabolic indices caused by berberin and extract, obtained from the bark of Phellodendron lavalei, introduced in subtropic regions of Georgia, in streptozotocin induced diabetic rats]. Georgian Med News, 2011
  308. [Antidiabetic activity of berberin and extract, obtained from the bark of Phellodendron lavalei, introduced in subtropic regions of Georgia, in streptozotocin induced diabetic rats]. Georgian Med News, 2011
  309. Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle. Toxicol Pathol, 2011
  310. Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. Behav Brain Res, 2011
  311. Antiurolithic effect of berberine is mediated through multiple pathways. Eur J Pharmacol, 2011
  312. Antidiarrheal activity, chemical and toxicity profile of Berberis aristata. Pharm Biol, 2011
  313. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism, 2011
  314. Toxicology and carcinogenesis studies of goldenseal root powder (Hydrastis Canadensis) in F344/N rats and B6C3F1 mice (feed studies). Natl Toxicol Program Tech Rep Ser, 2010
  315. [Preventive effects of berberine on experimental colon cancer and relationship with cyclooxygenase-2 expression]. Zhongguo Zhong Yao Za Zhi, 2010
  316. Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. Eur J Pharmacol, 2010
  317. [Effects of berberine on serum levels of inflammatory factors and inflammatory signaling pathway in obese mice induced by high fat diet]. Zhongguo Zhong Yao Za Zhi, 2010
  318. Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. Endocr J, 2010
  319. 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Bioorg Med Chem, 2010
  320. Effects of berberine against radiation-induced intestinal injury in mice. Int J Radiat Oncol Biol Phys, 2010
  321. Berberine inhibits PTP1B activity and mimics insulin action. Biochem Biophys Res Commun, 2010
  322. Berberine suppresses neuroinflammatory responses through AMP-activated protein kinase activation in BV-2 microglia. J Cell Biochem, 2010
  323. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol, 2010
  324. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia, 2010
  325. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur J Pharmacol, 2009
  326. Hepatoprotective effects of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced acute liver hepatotoxicity in rats. J Ethnopharmacol, 2009
  327. Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur J Pharmacol, 2009
  328. Berberine against gastrointestinal peptides elevation and mucous secretion in hyperthyroid diarrheic rats. Regul Pept, 2009
  329. Berberine inhibits human tongue squamous carcinoma cancer tumor growth in a murine xenograft model. Phytomedicine, 2009
  330. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab, 2009
  331. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab, 2009
  332. [Effects of berberine on cell proliferation, peroxisome proliferation activated receptor gamma, CAAT/enhancer binding protein mRNA and protein expression in 3T3-L1 pre-adipocytes]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2008
  333. Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus. Chin Med J (Engl), 2008
  334. Comparison of the antidiabetic activity of Berberis lyceum root extract and berberine in alloxan-induced diabetic rats. Phytother Res, 2008
  335. Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J (Engl), 2008
  336. Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats. Pharmazie, 2008
  337. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull, 2008
  338. Berberine acutely inhibits insulin secretion from beta-cells through 3',5'-cyclic adenosine 5'-monophosphate signaling pathway. Endocrinology, 2008
  339. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes, 2008
  340. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab, 2008
  341. [Effect of berberine on left ventricular remodeling in renovascular hypertensive rats]. Yao Xue Xue Bao, 2007
  342. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 2006
  343. Developmental toxicity evaluation of berberine in rats and mice. Birth Defects Res B Dev Reprod Toxicol, 2006
  344. [Effects of huanglian jiedu decoction on leptin and resistin in insulin resistive rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2006
  345. Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol Pharm Bull, 2005
  346. Effect of Alstonia scholaris in enhancing the anticancer activity of berberine in the Ehrlich ascites carcinoma-bearing mice. J Med Food, 2004
  347. Effect of apitherapy in piglets with preweaning diarrhea. Am J Chin Med, 2003
  348. [Effect of berberine on the differentiation of adipocyte]. Zhonghua Yi Xue Za Zhi, 2003
  349. Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer, 2002
  350. The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. J Pharmacol Exp Ther, 2000
  351. Anticachectic effects of Coptidis rhizoma, an anti-inflammatory herb, on esophageal cancer cells that produce interleukin 6. Cancer Lett, 2000
  352. The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine. Biol Pharm Bull, 1999
  353. Inhibitory effect of Coptidis Rhizoma and Scutellariae Radix on azoxymethane-induced aberrant crypt foci formation in rat colon. Biol Pharm Bull, 1998
  354. Do alpha-2 adrenoceptors modify coping strategies in rats? Psychopharmacology (Berl), 1995
  355. Berberine derivatives as antileishmanial drugs. Antimicrob Agents Chemother, 1990
  356. Natural protoberberine alkaloids from Enantia chlorantha, palmatine, columbamine and jatrorrhizine for thioacetamide-traumatized rat liver. Acta Anat (Basel), 1988
Lab studies 127
  1. Comparative Effects of Myo-Inositol, Metformin, Berberine, and Combination Therapy on Metabolic, Anthropometric and Hormonal Parameters in Women with Polycystic Ovary Syndrome: A 6-Month Observational Cohort Study. J Clin Med, 2026
  2. Berberine and celecoxib synergistically suppress non-small cell lung cancer with EGFR/AKT/COX-2-related signaling: network pharmacology, molecular docking and experimental validation. Front Pharmacol, 2026
  3. Beyond efficacy, integrated toxicological profiling reveals the preclinical safety of Berberis lycium Royle and its principal alkaloid, berberine. J Ethnopharmacol, 2026
  4. Berberine shows potential in mitigating PM2.5-induced breast cancer progression by inducing DNA damage and inhibiting error-prone DNA repair pathways. Apoptosis, 2026
  5. Starch-based intelligent indicator membranes with triple antioxidant activity for fruit preservation via self-assembled berberine-oligomeric proanthocyanidins nanoparticles encapsulating tea tree oil. Food Chem X, 2026
  6. Berberine and Metabolic Dysfunction-Associated Steatotic Liver Disease: Hope or Hype? Pharmacol Res Perspect, 2026
  7. Efficacy and tolerability of nutraceuticals and phytotherapics for antipsychotic-induced weight gain in schizophrenia spectrum disorders: Systematic review and meta-analysis. Pharmacopsychiatry, 2026
  8. Herbal Medicine and Metabolic Syndrome: Phytochemicals Targeting the Molecular Causes of Insulin Resistance and Related Comorbidities. Curr Diabetes Rev, 2026
  9. Enhanced Apparent Oral Bioavailability of Berberine Through BioSOLVE Technology: Pharmacokinetic Evaluation of Metaberine™. Cureus, 2026
  10. Efficacy and mechanism of topical Chinese herbal formulation JieZe-1 on female lower genital tract co-infection with HSV-2 and Candida albicans via upregulating the cGAS/STING/IFN-I pathway. J Ethnopharmacol, 2026
  11. Berberine-Loaded Chitosan-Succinylated Pullulan Composite Films for the Preservation of Fresh-Cut Apples. Polymers (Basel), 2026
  12. [Shared mechanisms of obesity and male infertility and prediction of natural therapeutics based on machine learning and single-cell sequencing]. Zhongguo Zhong Yao Za Zhi, 2026
  13. Berberine alleviates soybean meal-induced enteritis in hybrid yellow catfish (Pelteobagrus fulvidraco ♀ × Pelteobagrus vachelli ♂) by regulating intestinal microbiota and tryptophan metabolism. Anim Nutr, 2026
  14. Effects of dietary berberine hydrochloride on growth, immunity, meat quality, and fecal microbiota in broiler chickens. Front Vet Sci, 2026
  15. Multi-analytical dataset on Lekhaniya Mahakashaya: HRLC-MS/MS Orbitrap profiling, HPTLC fingerprinting with marker estimation, and FTIR spectroscopy. Data Brief, 2026
  16. Molecular mechanism of berberine in ameliorating leptin resistance and mitochondrial dysfunction through the TRIB1-C/EBPα axis in obesity. Chin Med, 2026
  17. Targeting G-protein-coupled receptors and gut microbiota: Ge-Lian Qi-Shen decoction elevates GLP-1 to combat non-alcoholic fatty liver disease. Chin Med, 2026
  18. Anticancer, Anti-Inflammatory, and Acute Toxicological Evaluation of the Novel Berberine Derivative BN-7. Chem Biodivers, 2026
  19. Pre-harvest application of co-assembled Berberine-integrated herbal hydrogel for enhancing strawberry quality and shelf life. Food Chem, 2026
  20. Antifungal chitosan-based lipoic acid/berberine sulfate composite film for suppressing Penicillium italicum and preserving mandarin fruit. Int J Biol Macromol, 2026
  21. Hepatic-Targeted Liposomes-Ginger-Derived Exosomes Hybrid Nanocarrier for Synergistic Alleviation of Obesity-Induced Nonalcoholic Steatohepatitis. Adv Healthc Mater, 2026
  22. Berberine-cinnamic acid co-crystal effect in ameliorating hyperlipidemia might be regulated through the PI3K/AKT/mTOR/SREBP-1 signaling pathway. FEBS Open Bio, 2026
  23. Vanadyl Acetylacetonate and Berberine Synergistically Ameliorate Diabetes-induced Vascular Dysfunction and Reduce Endothelial Toxicity through ERK and Akt Regulation. Biol Trace Elem Res, 2026
  24. LITAF-NOTCH2-Bmi-1 Axis Mediates AMPK-Dependent Inhibition of Gastric Cancer Invasion and Metastasis. FASEB J, 2025
  25. Berberine Repairs Intestinal Mucosal Barrier by Targeting HSP90AA1 and MAPK14. Pharmgenomics Pers Med, 2025
  26. The potential value of the use of berberine in depression: a systematic review and meta-analysis of preclinical studies. Front Pharmacol, 2025
  27. Synergistic potential of Berberine and Wogonin improved adipose inflammation and insulin resistance associated with obesity through HIF-α axis. Chin Med, 2025
  28. Berberine protects against gefitinib-induced liver injury by inhibiting the HMGB1/TLR4/NF-κB pathway. Front Pharmacol, 2025
  29. Mechanistic Perspectives on Radiation-Induced Skin Injury and the Protective Effects of Berberine. J Inflamm Res, 2025
  30. Investigating Neuroprotective Effects of Berberine on Mitochondrial Dysfunction and Autophagy Impairment in Parkinson's Disease. Int J Mol Sci, 2025
  31. Metformin and berberine synergistically improve NAFLD via the AMPK-SREBP1-FASN signaling pathway. Sci Rep, 2025
  32. Tianma Granules Alleviate AOM/DSS-Induced Colorectal Tumorigenesis by Inhibiting the Wnt/β-Catenin Pathway Activation. J Cell Mol Med, 2025
  33. Corrigendum to "Berberine for Appetite Suppressant and Prevention of Obesity". Biomed Res Int, 2025
  34. Exploring the potential of herbal drugs for treating liver fibrosis: a computational screening approach. Asian Biomed (Res Rev News), 2025
  35. Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles. Pharmaceutics, 2025
  36. Borderline hyperlipidemia: preventive supplementation with berberine phospholipids to prevent early atherosclerosis evolution. Minerva Med, 2025
  37. Jatrorrhizine retard obesity by modulating transcription factor c-Jun/c-Fos to downregulate Mmp12-mediated inflammation. Int Immunopharmacol, 2025
  38. A Review of the Antiviral Activity of Berberine. Curr Drug Discov Technol, 2025
  39. Targeting IGF1 to alleviate obesity through regulating energy expenditure and fat deposition. Sci China Life Sci, 2025
  40. Analyses of Off-Target Effects on Cardiac and Skeletal Muscles by Berberine, a Drug Used to Treat Cancers and Induce Weight Loss. Cytoskeleton (Hoboken), 2025
  41. Berberine alleviates fructose-induced hepatic injury via ADK/AMPK/Nrf2 pathway: A novel insight. Biomed Pharmacother, 2024
  42. Development of Proniosome Gel Formulation for CHIKV Infection. Pharmaceutics, 2024
  43. Charting Wellness in India: Piloting the iTHRIVE's Functional Nutrition Approach to Improve Glycaemic and Inflammatory Parameters in Prediabetes and Type 2 Diabetes Mellitus. Cureus, 2024
  44. Oxidative stress and plasma ceramides in broiler chickens. Front Physiol, 2024
  45. Exploration of Berberine Against Ulcerative Colitis via TLR4/NF-κB/HIF-1α Pathway by Bioinformatics and Experimental Validation. Drug Des Devel Ther, 2024
  46. Berberine promotes lacteal junction zippering and ameliorates diet-induced obesity through the RhoA/ROCK signaling pathway. Phytomedicine, 2024
  47. Autophagy-related biomarkers in preeclampsia: the underlying mechanism, correlation to the immune microenvironment and drug screening. BMC Pregnancy Childbirth, 2024
  48. Potential role of Akt in the regulation of fibroblast growth factor 21 by berberine. J Nat Med, 2024
  49. Borderline hyperlipidemia preventive management with Berberine PL in asymptomatic prevention of early atherosclerosis. Minerva Gastroenterol (Torino), 2024
  50. Thinking About Berberine. Integr Med (Encinitas), 2023
  51. Three arms, double-blind, non-inferiority, randomized clinical study testing the lipid-lowering effect of a novel dietary supplement containing red yeast rice and artichoke extracts compared to Armolipid Plus® and placebo. Arch Med Sci, 2023
  52. Berberine suppressed sarcopenia insulin resistance through SIRT1-mediated mitophagy. Open Life Sci, 2023
  53. Berberine chloride (dual topoisomerase I and II inhibitor) modulate mitochondrial uncoupling protein (UCP1) in molecular docking and dynamic with in-vitro cytotoxic and mitochondrial ATP production. J Biomol Struct Dyn, 2023
  54. Simiao Wan and its ingredients alleviate type 2 diabetes mellitus via IRS1/AKT2/FOXO1/GLUT2 signaling. Front Nutr, 2022
  55. Functional Complementation of Anti-Adipogenic Phytonutrients for Obesity Prevention and Management. Nutrients, 2022
  56. Jatrorrhizine Improves Endothelial Function in Diabetes and Obesity through Suppression of Endoplasmic Reticulum Stress. Int J Mol Sci, 2022
  57. Dietary berberine alleviates high carbohydrate diet-induced intestinal damages and improves lipid metabolism in largemouth bass (Micropterus salmoides). Front Nutr, 2022
  58. A Composition of Phytonutrients for Glycemic and Weight Management. Nutrients, 2022
  59. The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial. Med J Islam Repub Iran, 2022
  60. A co-crystal berberine-ibuprofen improves obesity by inhibiting the protein kinases TBK1 and IKKɛ. Commun Biol, 2022
  61. A Bibliometric Analysis of Research on the Links Between Gut Microbiota and Atherosclerosis. Front Cardiovasc Med, 2022
  62. Cellular and Molecular Mechanisms and Effects of Berberine on Obesity-Induced Inflammation. Biomedicines, 2022
  63. Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver Disease via Modulating Glucose and Lipid Metabolism and Restoring Gut Microbiota. Front Pharmacol, 2022
  64. Purification, biochemical characterization, and DPP-IV and α-amylase inhibitory activity of Berberine from Cardiospermum halicacabum. J Mol Recognit, 2022
  65. Dissecting the Effect of Berberine on the Intestinal Microbiome in the Weaned Piglets by Metagenomic Sequencing. Front Microbiol, 2022
  66. Natural bioactive constituents from herbs and nutraceuticals promote browning of white adipose tissue. Pharmacol Res, 2022
  67. Berberine represses Wnt/β-catenin pathway activation via modulating the microRNA-103a-3p/Bromodomain-containing protein 4 axis, thereby refraining pyroptosis and reducing the intestinal mucosal barrier defect induced via colitis. Bioengineered, 2022
  68. Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study. Cureus, 2022
  69. Uncoupling Protein 2 as a Pathogenic Determinant and Therapeutic Target in Cardiovascular and Metabolic Diseases. Curr Neuropharmacol, 2022
  70. Discovery of the First in Class 9-N-Berberine Derivative as Hypoglycemic Agent with Extra-Strong Action. Pharmaceutics, 2021
  71. A System-Level Mechanism of Anmyungambi Decoction for Obesity: A Network Pharmacological Approach. Biomolecules, 2021
  72. Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation. Front Oncol, 2021
  73. Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation. Front Pharmacol, 2021
  74. Exploring the Mechanism of Berberine Intervention in Ulcerative Colitis from the Perspective of Inflammation and Immunity Based on Systemic Pharmacology. Evid Based Complement Alternat Med, 2021
  75. Berberine Ameliorates Hepatic Insulin Resistance by Regulating microRNA-146b/SIRT1 Pathway. Diabetes Metab Syndr Obes, 2021
  76. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol, 2021
  77. Beneficial Metabolic Effect of a Nutraceuticals Combination (Monacolin K, Yeasted Red Rice, Polyphenolic Extract of Annurca Apple and Berberine) on Acquired Hypercholesterolemia: A Prospective Analysis. Metabolites, 2021
  78. In silico analysis of phytoconstituents from Tinospora cordifolia with targets related to diabetes and obesity. In Silico Pharmacol, 2021
  79. Improving sciatic nerve regeneration by using alginate/chitosan hydrogel containing berberine. Drug Deliv Transl Res, 2021
  80. Immune Competence and Minimizing Susceptibility to COVID-19 and Other Immune System Threats. Altern Ther Health Med, 2020
  81. Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle. Free Radic Biol Med, 2020
  82. Lagerstroemia speciosa (L.) Pers. triggers oxidative stress mediated apoptosis via intrinsic mitochondrial pathway in HepG2 cells. Environ Toxicol, 2020
  83. Berberine ameliorates obesity-induced chronic inflammation through suppression of ER stress and promotion of macrophage M2 polarization at least partly via downregulating lncRNA Gomafu. Int Immunopharmacol, 2020
  84. Apoptosis Activation in Thyroid Cancer Cells by Jatrorrhizine-Platinum(II) Complex via Downregulation of PI3K/AKT/Mammalian Target of Rapamycin (mTOR) Pathway. Med Sci Monit, 2020
  85. Combination of metformin and berberine represses the apoptosis of sebocytes in high-fat diet-induced diabetic hamsters and an insulin-treated human cell line. Cell Biochem Funct, 2020
  86. Development of a Selective Adsorbing Material for Binding of Pyrrolizidine Alkaloids in Herbal Extracts, Based on Molecular Group Imprinting. Planta Med, 2019
  87. Hypolipidemic effects of herbal extracts by reduction of adipocyte differentiation, intracellular neutral lipid content, lipolysis, fatty acid exchange and lipid droplet motility. Sci Rep, 2019
  88. Dopamine D1 receptor agonists inhibit lung metastasis of breast cancer reducing cancer stemness. Eur J Pharmacol, 2019
  89. Berberine Influences Blood Glucose via Modulating the Gut Microbiome in Grass Carp. Front Microbiol, 2019
  90. Berberine protects myocardial cells against anoxia-reoxygenation injury via p38 MAPK-mediated NF-κB signaling pathways. Exp Ther Med, 2019
  91. 8-Cetylcoptisine, a new coptisine derivative, induces mitochondria-dependent apoptosis and G0/G1 cell cycle arrest in human A549 cells. Chem Biol Interact, 2019
  92. The impact of Keap1/Nrf2, P38MAPK/NF-κB and Bax/Bcl2/caspase-3 signaling pathways in the protective effects of berberine against methotrexate-induced nephrotoxicity. Biomed Pharmacother, 2019
  93. Berberine Ameliorates Periodontal Bone Loss by Regulating Gut Microbiota. J Dent Res, 2019
  94. Proteomics analysis reveals a potential new target protein for the lipid-lowering effect of Berberine8998. Acta Pharmacol Sin, 2018
  95. Berberine ameliorates neonatal necrotizing enterocolitis by activating the phosphoinositide 3-kinase/protein kinase B signaling pathway. Exp Ther Med, 2018
  96. Neuroprotective effect of berberine against learning and memory deficits in diffuse axonal injury. Exp Ther Med, 2018
  97. Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways. Biomed Pharmacother, 2017
  98. Berberine alleviates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress. Exp Ther Med, 2017
  99. ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis. J Mol Endocrinol, 2016
  100. Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction. J Clin Diagn Res, 2016
  101. The roles of tricellular tight junction protein lipolysis-stimulated lipoprotein receptor in malignancy of human endometrial cancer cells. Oncotarget, 2016
  102. Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. PLoS One, 2016
  103. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. Biochem Biophys Res Commun, 2016
  104. A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine. Mol Biosyst, 2015
  105. Berberine activates thermogenesis in white and brown adipose tissue. Nat Commun, 2014
  106. Effects of berberine and red yeast on proinflammatory cytokines IL-6 and TNF-α in peripheral blood mononuclear cells (PBMCs) of human subjects. Front Pharmacol, 2014
  107. [Application of metabolomics in treating polycystic ovary syndrome with berberine based on ultra high performance liquid chromatography-mass spectrometry]. Se Pu, 2014
  108. Dietary and nutraceutical approach to type 2 diabetes. Arch Med Sci, 2014
  109. Effects of berberine on β-secretase activity in a rabbit model of Alzheimer's disease. Arch Med Sci, 2013
  110. Development of a cell-based high-throughput peroxisome proliferator-activated receptors (PPARs) screening model and its application for evaluation of the extracts from Rhizoma Coptis. J Asian Nat Prod Res, 2013
  111. Safety evaluation of main alkaloids from Rhizoma Coptidis. J Ethnopharmacol, 2013
  112. Mitochondrial inhibitor as a new class of insulin sensitizer. Acta Pharm Sin B, 2012
  113. Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer. Minerva Ginecol, 2012
  114. Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis. Mol Cell Endocrinol, 2012
  115. Possible therapeutic potential of berberine in diabetic osteopathy. Med Hypotheses, 2012
  116. Promotion of adiponectin multimerization by emodin: a novel AMPK activator with PPARγ-agonist activity. J Cell Biochem, 2012
  117. My microbiome and me. Science, 2012
  118. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med, 2012
  119. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol, 2012
  120. Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. Drug Chem Toxicol, 2012
  121. Adiponectin self-regulates its expression and multimerization in adipose tissue: an autocrine/paracrine mechanism? Med Hypotheses, 2012
  122. Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation. Eur J Pharmacol, 2010
  123. Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation. Fitoterapia, 2010
  124. Nutraceuticals for treatment of high blood pressure values in patients with metabolic syndrome. High Blood Press Cardiovasc Prev, 2009
  125. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. Cardiovasc Res, 2009
  126. Synthesis and antimicrobial activity of 3-alkoxyjatrorrhizine derivatives. Planta Med, 2008
  127. Anti-arthritic effects of Ephedra sinica STAPF herb-acupuncture: inhibition of lipopolysaccharide-induced inflammation and adjuvant-induced polyarthritis. J Pharmacol Sci, 2006
Reviews 104
  1. Therapeutic Potential of Berberine in Obesity-Associated Neuroinflammation Through Shared Molecular Pathways: TLR4/NF-κB/MAPK, ROS/NRF2 and NLRP3. Nutrients, 2026
  2. Phytochemicals and Irisin as Multi-Target Regulators of Adipose Tissue Browning and Metabolic Reprogramming: Synergies with GLP-1 Pathways. Antioxidants (Basel), 2026
  3. [Research progress on traditional Chinese medicine in prevention and treatment of metabolic diseases via SIRT1/AMPK signaling pathway]. Zhongguo Zhong Yao Za Zhi, 2026
  4. Comparative Efficacy of Herbal Products on Metabolic Parameters in Metabolic-Dysfunction Associated Liver Disease: A Systematic Review and Network Meta-Analysis. Gastro Hep Adv, 2026
  5. Metabolic and Anti-Inflammatory Effects of Berberine-Rationale for Its Therapeutic Potential in Polycystic Ovary Syndrome. Int J Mol Sci, 2026
  6. Dihydroberberine in metabolic disorders: Bioavailability, molecular mechanisms, toxicology, and future perspectives. Food Chem Toxicol, 2026
  7. Obesity-associated carcinogenesis with treatment gaps: A narrative review of updated evidence and natural products strategies. J Physiol Pharmacol, 2026
  8. Gut microbiome-blood cholesterol crosstalk: towards personalized strategies for dyslipidemia. Folia Microbiol (Praha), 2026
  9. Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions. Food Sci Nutr, 2026
  10. An overview on phytotherapeutics for metabolic syndrome: A journey from traditional knowledge to modern clinical validation. J Diabetes Metab Disord, 2026
  11. Potential Health Effects of the Natural Alkaloid Berberine: A Narrative Review. Nutr Rev, 2026
  12. Probiotics and Phytoantioxidants Target Coronary Endothelial Dysfunction in Irregular Sleep- and Obesity-Associated Cardiometabolic Syndrome. Life (Basel), 2025
  13. Metabolic regulation of obesity by naturally occurring compounds: mechanisms and therapeutic potential. Front Endocrinol (Lausanne), 2025
  14. Thyroid cancer: From molecular insights to therapy (Review). Oncol Lett, 2025
  15. Cardiovascular toxicity associated with supplement use. Clin Toxicol (Phila), 2025
  16. Botanical Antinutrients as Natural Modulators of Postprandial Hyperglycemia and Hyperlipidemia: A Narrative Review. Phytother Res, 2025
  17. Berberine as a Bioactive Alkaloid: Multi-Omics Perspectives on Its Role in Obesity Management. Metabolites, 2025
  18. Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives. Int J Mol Sci, 2025
  19. Traditional Chinese medicine modulates hypothalamic neuropeptides for appetite regulation: A comprehensive review. Biosci Trends, 2025
  20. A Review of the Mechanisms of Astragaloside IV and Berberine in Vascular Dysfunction Associated with Obesity and Diabetes. Drug Des Devel Ther, 2025
  21. Anti-neurodegenerative treatment in Alzheimer's disease: Multifaceted mechanisms of action of berberine. Int J Clin Pharmacol Ther, 2025
  22. The Role of Nutraceuticals and Probiotics in Addition to Lifestyle Intervention in the Management of Childhood Obesity-Part 1: Metabolic Changes. Nutrients, 2025
  23. Endocrine regulation of metabolic crosstalk between liver and brown adipose tissue by natural active ingredients. Int J Obes (Lond), 2025
  24. Berberine-induced browning and energy metabolism: mechanisms and implications. PeerJ, 2025
  25. Phytochemicals in Obesity Management: Mechanisms and Clinical Perspectives. Curr Nutr Rep, 2025
  26. Relevance of Indian Traditional Herbal Brews for Gut Microbiota Balance. Indian J Microbiol, 2024
  27. Protein Kinases in Obesity, and the Kinase-Targeted Therapy. Adv Exp Med Biol, 2024
  28. Targeting lipid droplets and lipid droplet-associated proteins: a new perspective on natural compounds against metabolic diseases. Chin Med, 2024
  29. Innovative treatments for obesity and NAFLD: A bibliometric study on antioxidants, herbs, phytochemicals, and natural compounds. Heliyon, 2024
  30. Effects of different natural products in patients with non-alcoholic fatty liver disease-A network meta-analysis of randomized controlled trials. Phytother Res, 2024
  31. The therapeutic potential of typical plant-derived compounds for the management of metabolic disorders. Phytother Res, 2024
  32. Management of Colorectal Cancer Using Nanocarriers-based Drug Delivery for Herbal Bioactives: Current and Emerging Approaches. Curr Pharm Biotechnol, 2024
  33. Clinically Effective Molecules of Natural Origin for Obesity Prevention or Treatment. Int J Mol Sci, 2024
  34. Anti-inflammatory, antioxidant, and immunomodulatory effects of Berberis vulgaris and its constituent berberine, experimental and clinical, a review. Phytother Res, 2024
  35. Recent Insight into Herbal Bioactives-based Novel Approaches for Chronic Intestinal Inflammatory Disorders Therapy. Curr Pharm Biotechnol, 2024
  36. Berberine: Pharmacological Features in Health, Disease and Aging. Curr Med Chem, 2024
  37. Phytochemicals for the treatment of metabolic diseases: Evidence from clinical studies. Biomed Pharmacother, 2023
  38. Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism. Front Pharmacol, 2023
  39. Phytochemicals and Regulation of NF-kB in Inflammatory Bowel Diseases: An Overview of In Vitro and In Vivo Effects. Metabolites, 2023
  40. Plant-food-derived Bioactives in Managing Hypertension: From Current Findings to Upcoming Effective Pharmacotherapies. Curr Top Med Chem, 2023
  41. Role of herbal medicine and gut microbiota in the prevention and treatment of obesity. J Ethnopharmacol, 2023
  42. Berberine a traditional Chinese drug repurposing: Its actions in inflammation-associated ulcerative colitis and cancer therapy. Front Immunol, 2022
  43. Pharmacokinetic of berberine, the main constituent of Berberis vulgaris L.: A comprehensive review. Phytother Res, 2022
  44. Berberine as a potential agent for breast cancer therapy. Front Oncol, 2022
  45. The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Front Cell Infect Microbiol, 2022
  46. Anticancer Effects and Mechanisms of Berberine from Medicinal Herbs: An Update Review. Molecules, 2022
  47. Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends. Molecules, 2022
  48. Promising Antioxidative Effect of Berberine in Cardiovascular Diseases. Front Pharmacol, 2022
  49. Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease. Molecules, 2022
  50. A patent review of berberine and its derivatives with various pharmacological activities (2016-2020). Expert Opin Ther Pat, 2022
  51. It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them? Int J Mol Sci, 2021
  52. Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota. Front Pharmacol, 2021
  53. Adipose and non-adipose perspectives of plant derived natural compounds for mitigation of obesity. J Ethnopharmacol, 2021
  54. Treatment for liver cancer: From sorafenib to natural products. Eur J Med Chem, 2021
  55. Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview. Eur J Med Chem, 2021
  56. Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease. Mini Rev Med Chem, 2021
  57. Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacol Res, 2021
  58. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. Biomed Pharmacother, 2021
  59. Berberine in the Treatment of Diabetes Mellitus: A Review. Endocr Metab Immune Disord Drug Targets, 2021
  60. Effects of Berberine on the Gastrointestinal Microbiota. Front Cell Infect Microbiol, 2020
  61. Econutrition, brown and beige fat tissue and obesity. Asia Pac J Clin Nutr, 2020
  62. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. Clin Transl Allergy, 2020
  63. Biological properties and clinical applications of berberine. Front Med, 2020
  64. The Quest to Enhance the Efficacy of Berberine for Type-2 Diabetes and Associated Diseases: Physicochemical Modification Approaches. Biomedicines, 2020
  65. Feeding brown fat: dietary phytochemicals targeting non-shivering thermogenesis to control body weight. Proc Nutr Soc, 2020
  66. Berberine pharmacology and the gut microbiota: A hidden therapeutic link. Pharmacol Res, 2020
  67. Polycystic ovary syndrome management: a review of the possible amazing role of berberine. Arch Gynecol Obstet, 2020
  68. The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials. Evid Based Complement Alternat Med, 2019
  69. [Berberine as a potential therapeutic agent in the treatment of acute pancreatitis]. Postepy Biochem, 2019
  70. Phytochemicals as potential candidates to combat obesity via adipose non-shivering thermogenesis. Pharmacol Res, 2019
  71. Gut microbiota in phytopharmacology: A comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions. Pharmacol Res, 2019
  72. [Molecular mechanisms of insulin resistance and interventional effects of Chinese herbal medicine]. Zhongguo Zhong Yao Za Zhi, 2019
  73. The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease. High Blood Press Cardiovasc Prev, 2019
  74. Using herbal medicine to target the "microbiota-metabolism-immunity" axis as possible therapy for cardiovascular disease. Pharmacol Res, 2019
  75. Dietary polyphenols and their roles in fat browning. J Nutr Biochem, 2019
  76. Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation. Am J Transl Res, 2018
  77. Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action. Diabetes Metab Syndr Obes, 2018
  78. Nutritional Modulation of AMPK-Impact upon Metabolic-Inflammation. Int J Mol Sci, 2018
  79. Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes. Expert Opin Pharmacother, 2018
  80. Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? Anticancer Res, 2018
  81. Chinese Medicine in the Battle Against Obesity and Metabolic Diseases. Front Physiol, 2018
  82. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. Oncotarget, 2018
  83. New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome. Cureus, 2017
  84. Uncoupling Protein 2: A Key Player and a Potential Therapeutic Target in Vascular Diseases. Oxid Med Cell Longev, 2017
  85. Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease. Curr Pharm Des, 2017
  86. Nutraceutical approaches to metabolic syndrome. Ann Med, 2017
  87. A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iran J Basic Med Sci, 2017
  88. Dietary Factors Promoting Brown and Beige Fat Development and Thermogenesis. Adv Nutr, 2017
  89. Rhizoma Coptidis: A Potential Cardiovascular Protective Agent. Front Pharmacol, 2016
  90. Novel nutraceutic therapies for the treatment of metabolic syndrome. World J Diabetes, 2016
  91. Role of phytochemicals in the management of metabolic syndrome. Phytomedicine, 2016
  92. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? J Ethnopharmacol, 2016
  93. Pharmacological effects of berberine and its derivatives: a patent update. Expert Opin Ther Pat, 2016
  94. A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L. Avicenna J Phytomed, 2015
  95. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. Atherosclerosis, 2015
  96. Active ingredients from natural botanicals in the treatment of obesity. Obes Rev, 2014
  97. From arrow poison to herbal medicine--the ethnobotanical, phytochemical and pharmacological significance of Cissampelos (Menispermaceae). J Ethnopharmacol, 2014
  98. Nutraceuticals for metabolic syndrome management: from laboratory to benchside. Curr Vasc Pharmacol, 2014
  99. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med Sci Monit, 2011
  100. Targeting metabolic syndrome: candidate natural agents. J Diabetes, 2010
  101. Role of endothelin receptor A and NADPH oxidase in vascular abnormalities. Vasc Health Risk Manag, 2010
  102. Antiatherogenic properties of flavonoids: implications for cardiovascular health. Can J Cardiol, 2010
  103. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N Biotechnol, 2009
  104. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets, 2008
Other papers, not yet read by us 60
  1. Diet-driven cardiometabolic dysfunction as a potential amplifier of antimicrobial resistance: mechanistic evidence, gut resistome ecology, and dual-action nutraceutical interventions. Front Public Health, 2026
  2. Coptidis Rhizoma for Obesity, Diabetes, and Dyslipidemia: An Integrated Meta-Analysis and In Silico Study. Int J Mol Sci, 2026
  3. Comparative anti-obesity efficacy of high-interest natural products in preclinical models: a bibliometric and network meta-analysis. Food Funct, 2026
  4. Considerations for Dietary Supplements after GLP-1RA Treatment: A Narrative Review. J Nutr, 2026
  5. Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case-control study. Front Endocrinol (Lausanne), 2026
  6. Efficacy of pharmacological and nutritional interventions for glucose dysfunction in schizophrenia-A systematic review and network meta-analysis. J Psychopharmacol, 2026
  7. The Influence of Berberine on Vascular Function Parameters, Among Them VEGF, in Individuals with MAFLD: A Double-Blind, Randomized, Placebo-Controlled Trial. Nutrients, 2025
  8. [Shared Therapeutic Targets of Obesity and Type 2 Diabetes Mellitus and the Intervention Mechanisms of Chinese Herbal Components]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2025
  9. Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia, and Glycemic Response Improvement in a 60-year-Old Male with Metabolic Syndrome Through a Personalized Six-Month Nutraceutical/Diet Protocol: A Case Report. Altern Ther Health Med, 2025
  10. Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence. Eur J Med Res, 2025
  11. Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-Analysis. Phytother Res, 2025
  12. Obesity: pathophysiology and therapeutic interventions. Mol Biomed, 2025
  13. Berberine and health outcomes: an overview of systematic reviews. BMC Complement Med Ther, 2025
  14. HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clin Mol Hepatol, 2025
  15. Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open, 2025
  16. Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review. Nutrients, 2025
  17. Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes. Physiol Rep, 2024
  18. Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study. Nutrients, 2024
  19. Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial. J Physiol Pharmacol, 2024
  20. [Investigation of the effects and mechanisms of berberine on a mouse model of polycystic ovary syndrome: based on intestinal flora analysis]. Zhonghua Fu Chan Ke Za Zhi, 2024
  21. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med, 2024
  22. The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials. Clin Ther, 2024
  23. Revealing the improvement of diabetes by Si Wei Jiang Huang Tang San through ERK/HIF1α signaling pathway via network pharmacology. J Ethnopharmacol, 2024
  24. Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection. Int J STD AIDS, 2023
  25. Berberine in Non-Alcoholic Fatty Liver Disease-A Review. Nutrients, 2022
  26. Effect of berberine and bicyclol on Chinese patients with nonalcoholic fatty liver disease: a retrospective study. Postgrad Med, 2022
  27. The effect of barberry (Berberis integerrima) on lipid profile and systemic inflammation in subjects with cardiovascular risk factors: a randomized controlled trial. BMC Complement Med Ther, 2022
  28. Dietary supplements in therapy to support weight reduction in obese patients. Acta Sci Pol Technol Aliment, 2022
  29. Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin. Asian J Psychiatr, 2022
  30. Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine. Am J Chin Med, 2021
  31. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxid Med Cell Longev, 2021
  32. Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study. Nutrients, 2021
  33. Medicinal Plants and Phytochemicals Regulating Insulin Resistance and Glucose Homeostasis in Type 2 Diabetic Patients: A Clinical Review. Adv Exp Med Biol, 2021
  34. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res, 2021
  35. Efficacy and Safety of Armolipid Plus®: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Nutrients, 2021
  36. Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial. Trials, 2021
  37. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biol Sex Differ, 2021
  38. Remission of new-onset type 2 diabetes mellitus in an adolescent using an integrative medicine approach: A case report. J Integr Med, 2021
  39. Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine. Endocr Metab Immune Disord Drug Targets, 2021
  40. The effect and safety of Berberine on polycystic ovary syndrome: a systematic review. J Obstet Gynaecol, 2021
  41. The effect of Berberine on weight loss in order to prevent obesity: A systematic review. Biomed Pharmacother, 2020
  42. A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Nutr, 2020
  43. The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension. High Blood Press Cardiovasc Prev, 2019
  44. Targeting AMPK signaling pathway by natural products for treatment of diabetes mellitus and its complications. J Cell Physiol, 2019
  45. NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial. Atherosclerosis, 2019
  46. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. Am J Physiol Endocrinol Metab, 2019
  47. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. Nutrients, 2018
  48. A Polyphenol-Based Multicomponent Nutraceutical in Dysmetabolism and Oxidative Stress: Results from a Pilot Study. J Diet Suppl, 2018
  49. A 13-week low glycemic load diet and lifestyle modification program combining low glycemic load protein shakes and targeted nutraceuticals improved weight loss and cardio-metabolic risk factors. Can J Physiol Pharmacol, 2017
  50. Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study. Int J Mol Sci, 2017
  51. Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. J Biol Regul Homeost Agents, 2017
  52. [Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2016
  53. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS One, 2014
  54. Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia. High Blood Press Cardiovasc Prev, 2014
  55. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf), 2014
  56. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord, 2013
  57. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin Biol Ther, 2013
  58. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol, 2012
  59. The effects of berberine on the magnitude of the acute inflammatory response induced by Escherichia coli lipopolysaccharide in broiler chickens. Poult Sci, 2010
  60. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis, 2010

Other conditions Berberine has been studied for

Checked against PubMed on 2026-10-28. Everything we know about Berberine